Skip to main content


Table 2 Therapeutic suggestions using the Connectivity Map

From: Transcriptomics profiling study of breast cancer from Kingdom of Saudi Arabia revealed altered expression of Adiponectin and Fatty Acid Binding Protein4: Is lipid metabolism associated with breast cancer?

Pharmaceutical perturbagen Connectivity score Description
Hydrocortisone -0.97 Alimentary tract and metabolism (Aid in fat, protein and carbohydrate metabolism)
Fulvestrant * -0.952 Estrogen receptor antagonist
Gliclazide -0.934 Potent antiatherogenic effect in type 2 diabetes
Deoxycortone -0.917 Corticosteroids for systemic use
Sirolimus -0.909 Antineoplastic and immunomodulating agents
Glimepiride -0.905 Sulfonylurea anti-diabetic drug
Repaglinide -0.895 Treatment of type II diabetes
Methotrexate * -0.89 Treatment of a number of cancers including breast
Letrozole * -0.882 Non-steroidal aromatase inhibitor for the treatment of hormonally-responsive breast cancer after surgery
Glipizide -0.878 Anti-diabetic drug from the sulfonylurea class
Doxorubicin * -0.868 Treatment of a number of cancers including breast
Glibenclamide -0.867 Antidiabetic drug in a class of medications known as sulfonylureas
Tamoxifen * -0.759 Antagonist of the estrogen receptor in breast tissue
  1. Results of cmap for compounds with expression signatures opposite those of loaded gene expression levels for breast cancer.
  2. * Approved by the FDA for breast cancer